Abstract
Multiple myeloma is a plasma cell neoplasm that predominantly occurs in the elderly, which has preceding benign stages, the so-called MGUS and smoldering myeloma. The precise definition of the various stages of the plasma cell neoplasms is critical to decide when therapy initiation is indicated. Traditionally, therapy was started when patients had overt evidence of end-organ damage, best remembered by the acronym CRAB. Clinical features included evidence of bone destruction, hypercalcemia, renal insufficiency, or anemia. More recently the International Myeloma Working Group has reclassified high-risk smoldering myeloma patients, at high risk of progression (80% at 2 years), as active myeloma and in need of therapy. The three expanded criteria include extreme deviation in the serum free light chain ratio (FLC ratio ≥100, with a minimal involved FLC level of at least 100 mg/L), two or more lesions on MRI, and also an extreme plasmacytosis (≥60%). These criteria allow us to initiate therapy before end-organ damage hopefully preventing long-lasting complications for patients. In addition to the standard clinical criteria, physicians should test for the genetic subtypes of the disease. Understanding the various genetic subtypes has allowed for a better prognostic categorization of patients and most recently has allowed for the development of specific therapeutic approaches for subsets of the disease.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Similar content being viewed by others
References
Bartel TB, Haessler J, Brown TL et al (2009) F18-fluorodeoxyglucose positron emission tomography in the context of other imaging techniques and prognostic factors in multiple myeloma. Blood 114:2068–2076
Bianchi G, Kyle RA, Larson DR et al (2013) High levels of peripheral blood circulating plasma cells as a specific risk factor for progression of smoldering multiple myeloma. Leukemia 27:680–685
Cavo M, Tacchetti P, Patriarca F et al (2010) Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after, double autologous stem-cell transplantation in newly diagnosed multiple myeloma: a randomised phase 3 study. Lancet 376:2075–2085
Dhodapkar MV, Sexton R, Waheed S et al (2014) Clinical, genomic, and imaging predictors of myeloma progression from asymptomatic monoclonal gammopathies (SWOG S0120). Blood 123:78–85
Dimopoulos MA, Hillengass J, Usmani S et al (2015) Role of magnetic resonance imaging in the management of patients with multiple myeloma: a consensus statement. J Clin Oncol Off J Am Soc Clin Oncol 33:657–664
Dispenzieri A, Kyle RA, Katzmann JA et al (2008) Immunoglobulin free light chain ratio is an independent risk factor for progression of smoldering (asymptomatic) multiple myeloma. Blood 111:785–789
Dispenzieri A, Kyle R, Merlini G et al (2009) International myeloma working group guidelines for serum-free light chain analysis in multiple myeloma and related disorders. Leukemia 23:215–224
Durie BG, Salmon SE (1975) A clinical staging system for multiple myeloma. Correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival. Cancer 36:842–854
Durie BGM, Harousseau J-L, Miguel JS et al (2006) International uniform response criteria for multiple myeloma. Leukemia 20:1467–1473
Gonsalves WI, Leung N, Rajkumar SV et al (2015) Improvement in renal function and its impact on survival in patients with newly diagnosed multiple myeloma. Blood Cancer J 5:e296
Greenberg AJ, Rajkumar SV, Therneau TM, Singh PP, Dispenzieri A, Kumar SK (2014) Relationship between initial clinical presentation and the molecular cytogenetic classification of myeloma. Leukemia 28:398–403
Greipp PR, San Miguel JF, Durie BG et al (2005) International staging system for multiple myeloma. J Clin Oncol 23:3412–3420
Hari PN, Zhang MJ, Roy V et al (2009) Is the international staging system superior to the Durie-Salmon staging system? A comparison in multiple myeloma patients undergoing autologous transplant. Leukemia 23:1528–1534
Hillengass J, Fechtner K, Weber MA et al (2010) Prognostic significance of focal lesions in whole-body magnetic resonance imaging in patients with asymptomatic multiple myeloma. J Clin Oncol Off J Am Soc Clin Oncol 28:1606–1610
Hutchison CA, Batuman V, Behrens J et al (2012) The pathogenesis and diagnosis of acute kidney injury in multiple myeloma. Nat Rev Nephrol 8:43–51
Kastritis E, Terpos E, Moulopoulos L et al (2012) Extensive bone marrow infiltration and abnormal free light chain ratio identifies patients with asymptomatic myeloma at high risk for progression to symptomatic disease. Leukemia 27:947–953
Kastritis E, Moulopoulos LA, Terpos E, Koutoulidis V, Dimopoulos MA (2014) The prognostic importance of the presence of more than one focal lesion in spine MRI of patients with asymptomatic (smoldering) multiple myeloma. Leukemia 28:2402–2403
Kumar S, Fonseca R, Ketterling RP et al (2012) Trisomies in multiple myeloma: impact on survival in patients with high-risk cytogenetics. Blood 119:2100–2105
Kumar SK, Dispenzieri A, Lacy MQ et al (2014) Continued improvement in survival in multiple myeloma: changes in early mortality and outcomes in older patients. Leukemia 28:1122–1128
Kyle RA, Therneau TM, Rajkumar SV et al (2002) A long-term study of prognosis of monoclonal gammopathy of undetermined significance. N Engl J Med 346:564–569
Kyle RA, Remstein ED, Therneau TM et al (2007) Clinical course and prognosis of smoldering (asymptomatic) multiple myeloma. N Engl J Med 356:2582–2590
Larsen JT, Kumar SK, Dispenzieri A, Kyle RA, Katzmann JA, Rajkumar SV (2013) Serum free light chain ratio as a biomarker for high-risk smoldering multiple myeloma. Leukemia 27:941–946
Mateos M-V, Hernández M-T, Giraldo P et al (2013) Lenalidomide plus dexamethasone for high-risk smoldering multiple myeloma. N Engl J Med 369:438–447
Neben K, Jauch A, Hielscher T et al (2013) Progression in smoldering myeloma is independently determined by the chromosomal abnormalities del(17p), t(4;14), gain 1q, hyperdiploidy, and tumor load. J Clin Oncol Off J Am Soc Clin Oncol 31:4325–4332
Palumbo A, Bringhen S, Mateos MV et al (2015a) Geriatric assessment predicts survival and toxicities in elderly myeloma patients: an international myeloma working group report. Blood 125:2068–2074
Palumbo A, Avet-Loiseau H, Oliva S et al (2015b) Revised international staging system for multiple myeloma: a report from international myeloma working group. J Clin Oncol Off J Am Soc Clin Oncol 33:2863–2869
Pandey S, Rajkumar SV, Kapoor P et al (2013) Impact of FISH abnormalities on response to lenalidomide in patients with multiple myeloma. Blood 122:3210
Perez-Persona E, Vidriales MB, Mateo G et al (2007) New criteria to identify risk of progression in monoclonal gammopathy of uncertain significance and smoldering multiple myeloma based on multiparameter flow cytometry analysis of bone marrow plasma cells. Blood 110:2586–2592
Rajkumar SV (2011) Treatment of multiple myeloma. Nat Rev Clin Oncol 8:479–491
Rajkumar SV, Gahrton G, Bergsagel PL (2011a) Approach to the treatment of multiple myeloma: a clash of philosophies. Blood 118:3205–3211
Rajkumar SV, Larson D, Kyle RA (2011b) Diagnosis of smoldering multiple myeloma. N Engl J Med 365:474–475
Rajkumar SV, Merlini G, San Miguel JF (2012) Redefining myeloma. Nat Rev Clin Oncol 9:494–496
Rajkumar SV, Gupta V, Fonseca R et al (2013) Impact of primary molecular cytogenetic abnormalities and risk of progression in smoldering multiple myeloma. Leukemia 27:1738–1744
Rajkumar SV, Dimopoulos MA, Palumbo A et al (2014) International myeloma working group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol 15:e538–e548
Rajkumar SV, Landgren O, Mateos MV (2015) Smoldering multiple myeloma. Blood 125:3069–3075
Regelink JC, Minnema MC, Terpos E et al (2013) Comparison of modern and conventional imaging techniques in establishing multiple myeloma-related bone disease: a systematic review. Br J Haematol 162:50–61
Rosinol L, Blade J, Esteve J et al (2003) Smoldering multiple myeloma: natural history and recognition of an evolving type. Br J Haematol 123:631–636
Russell SJ, Rajkumar SV (2011) Multiple myeloma and the road to personalised medicine. Lancet Oncol 12:617–619
Siontis B, Kumar S, Dispenzieri A et al (2015) Positron emission tomography-computed tomography in the diagnostic evaluation of smoldering multiple myeloma: identification of patients needing therapy. Blood Cancer J 5:e364
Sonneveld P, Schmidt-Wolf IGH, van der Holt B et al (2012) Bortezomib induction and maintenance treatment in patients with newly diagnosed multiple myeloma: results of the randomized phase III HOVON-65/GMMG-HD4 trial. J Clin Oncol 30:2946–2955
Vu T, Gonsalves W, Kumar S et al (2015) Characteristics of exceptional responders to lenalidomide-based therapy in multiple myeloma. Blood Cancer J 5:e363
Waxman AJ, Mick R, Garfall AL et al (2014) Modeling the risk of progression in smoldering multiple myeloma. J Clin Oncol 32:A8607
Zamagni E, Nanni C, Patriarca F et al (2007) A prospective comparison of 18F-fluorodeoxyglucose positron emission tomography-computed tomography, magnetic resonance imaging and whole-body planar radiographs in the assessment of bone disease in newly diagnosed multiple myeloma. Haematologica 92:50–55
Acknowledgements
Supported in part by grants CA 107476 and CA 168762 from the National Cancer Institute, Rockville, MD, USA, and Asociación Española Contra el Cáncer (GCB120981SAN), Spain.
Authorship Contribution Statement
SVR, RF, and JFS conceived the paper, researched the literature, and wrote the manuscript.
Disclosure of Conflicts of Interest
SVR and JSM declare no conflict of interest. RF has received a patent for the prognostication of MM based on genetic categorization by FISH of the disease.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2018 Springer International Publishing Switzerland
About this chapter
Cite this chapter
Rajkumar, S.V., Fonseca, R., San Miguel, J.F. (2018). Diagnosis and Staging of Multiple Myeloma and Related Disorders. In: Dimopoulos, M., Facon, T., Terpos, E. (eds) Multiple Myeloma and Other Plasma Cell Neoplasms. Hematologic Malignancies. Springer, Cham. https://doi.org/10.1007/978-3-319-25586-6_2
Download citation
DOI: https://doi.org/10.1007/978-3-319-25586-6_2
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-319-25584-2
Online ISBN: 978-3-319-25586-6
eBook Packages: MedicineMedicine (R0)